This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
WCET 2024
SUPS 2024
BCAN TT 2024
SNMMI 2024
ASCO 2024
AUA 2024
All Conferences
View All
PCF
UroToday Home
Recent Abstracts
Urologic Oncology
Prostate Cancer
Recent Abstracts
AUA 2011 - Long term complications in men after radical prostatectomy who have early or late radiation - Session Highlights
May 18, 2011
AUA 2011 - 5-alpha reductase inhibitors diminish the rate of progression in men with low risk prostate cancer on active surveillance - Session Highlights
May 18, 2011
AUA 2011 - Age and aggressive prostate cancer in patients with low risk characteristics. Implications for conservative management - Session Highlights
May 18, 2011
AUA 2011 - Previously developed systems-based biopsy model (Prostate Px+) identifies favorable-risk prostate cancer for men enrolled in an active surveillance program - Session Highlights
May 18, 2011
AUA 2011 - Effect of radical prostatectomy on penile shortening - Session Highlights
May 18, 2011
AUA 2011 - Characterization of ureter, bladder, and bowel tissue injury after compression with robotic instruments - Session Highlights
May 18, 2011
AUA 2011 - Postoperative pain after pure and robot-assisted laparoscopic radical prostatectomy. A prospective randomized study - Session Highlights
May 18, 2011
AUA 2011 - Abiraterone acetate plus low-dose prednisone has a favorable safety profile, improves survival and produces PSA and radiographic responses in metastatic castration-resistant prostate cancer progressing after docetaxel-based chemotherapy: Result
May 17, 2011
AUA 2011 - Regulatory role of miR-203 in prostate cancer progression and metastasis - Session Highlights
May 17, 2011
AUA 2011 - Utilizing metformin to enhance the efficacy of androgen deprivation therapy in the treatment of prostate cancer - Session Highlights
May 17, 2011
AUA 2011 - Phase III study of intermittent MAB vs. continuous MAB - Session Highlights
May 17, 2011
AUA 2011 - Avoiding androgen deprivation therapy in men with high risk prostate cancer: The role of radical prostatectomy as initial treatment - Session Highlights
May 17, 2011
AUA 2011 - Target specific and dye encapsulated micelle probes for the detection of extra-prostate cancer during robotic-assisted laparoscopic prostatectomy (RALP) - Session Highlights
May 17, 2011
AUA 2011 - Current treatment patterns and characteristics of castration resistant prostate cancer (CRPC) patients; a European survey - Session Highlights
May 17, 2011
AUA 2011 - Can an early PSA rule out subsequent advanced prostate cancer? Long term risk of advanced cancer in men with low PSA levels at age below 50 - Session Highlights
May 17, 2011
AUA 2011 - The value of computed tomography in detecting prostate cancer lymph node metastasis is limited even in contemporary patients with very high risk of nodal involvement - Session Highlights
May 17, 2011
AUA 2011 - Men with isolated high grade prostatic intraepithelial neoplasia (HGPIN) have a high risk of prostate cancer in long-term follow-up: Results from a prospective multicenter, randomized, placebo-controlled prostate cancer prevention trial - Sessi
May 17, 2011
AUA 2011 - Prostate cancer detection rates, risk factors, and distribution with transperineal mapping template prostate biopsy: initial single institution experience - Session Highlights
May 17, 2011
AUA 2011 - Potency outcomes in patients who had multiple biopsies before radical prostatectomy for the treatment of localized prostate cancer - Session Highlights
May 17, 2011
AUA 2011 - Evaluation of the prostate health index (PHI) in the 2 to 4, and 4 to 10 ng/ml PSA ranges: Results from a multi-site, prospective, clinical evaluation - Session Highlights
May 17, 2011
Page 1377 of 1415
Start
Prev
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
Next
End
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free